Celldex drops as Pfizer dumps rindopepimut
This article was originally published in Scrip
Executive Summary
Celldex Therapeutics suffered a sharp drop in its share price, wiping almost $40 million off its value to $113 million, following news that Pfizer is terminating their collaboration over rindopepimut, an investigational brain cancer vaccine that was the subject of a $440 million deal signed in 2008, which included a $40 million upfront payment.